Description
The 2025 ASCO Genitourinary Cancers Symposium offers a premier platform for multidisciplinary experts to present and discuss the most current clinical and scientific advancements in genitourinary oncology. Attendees will gain insights from leading researchers and practitioners through oral abstract sessions, case-based discussions, keynote lectures, poster presentations, and networking events. The symposium features dedicated programming across prostate, urothelial, renal, testicular, and rare GU cancers, with a strong focus on translational science and emerging therapies.
Key sessions will highlight innovations in radioligand therapies, ctDNA biomarkers, antibody-drug conjugates (ADCs), and immunotherapy resistance strategies. Opportunities for interaction include rapid-fire abstract sessions, focused poster walks, early-career and women’s networking events, and engaging panel Q&As throughout.
Program Highlights at a Glance
Thursday, February 13, 2025 – Focus on Prostate Cancer
Oral Abstracts: Latest trial outcomes including TALAPRO-2, STOPCAP, and PORTOS validation
Radioligand Therapy Session: PSMA-based treatment strategies and ctDNA correlations
Case-Based Discussions: Biochemical recurrence and salvage therapy management
Keynote Address: William L. Dahut, MD – “Creative Innovation: Driving Science to Improve Patient-Centered Care”
Poster Sessions & Rapid Abstracts: New clinical data on androgen deprivation, diet, gut health, and ARPI combinations
Friday, February 14, 2025 – Focus on Urothelial Carcinoma and Germ Cell Tumors
Oral Abstracts: CheckMate 274, NIAGARA, and novel neoadjuvant combinations
Case-Based Panels: Non-muscle invasive bladder cancer & advanced treatment sequencing
Breakout: Innovations in germ cell tumor management and high-dose chemotherapy
ADCs Session: HER2 targeting, combination regimens, and toxicity management
ctDNA Session: Biomarker-driven strategies for bladder cancer treatment planning
Poster Sessions & Rapid Abstracts: FGFR3 inhibitors, Dato-DXd, enfortumab-pembro (EV-302), and RETAIN-2 trial
Saturday, February 15, 2025 – Focus on Renal, Adrenal, Penile, and Rare GU Cancers
Oral Abstracts: COSMIC-313, CheckMate 9ER, KEYMAKER-U03
Biomarker and Adjuvant Therapy Session: RCC-specific predictive markers and post-surgical therapies
Poster & Networking Events: Women in GU Cancers, Poster Walks across RCC, adrenal, penile, and testicular cancers
Rapid Abstracts: Trials on cemiplimab, ctDNA in papillary RCC, and disparities in outcomes
Closing Case-Based Panel: Strategies after immunotherapy failure in RCC
